Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis

Figure 1 Systemic IL-9 in healthy individuals and patients with active and inactive inflammatory bowel disease. Data presented as medians with 95%CI and analyzed using Kruskal-Wallis H test. ¹Significantly different from other groups.

Figure 2 Systemic IL-9 in patients with active and inactive Crohn’s disease and ulcerative colitis. Data presented as geometric means with 95%CI and analyzed using one-way ANOVA. Small letters indicate statistical significance of between-group differences.

Figure 3 Correlation between the concentrations of circulating IL9 and the clinical activity of Crohn’s disease and ulcerative colitis. Data analyzed using Spearman correlation test. CDAI: Crohn’s Disease Activity Index; MDAI: Mayo Disease Activity Index.

Figure 4 Correlation between the concentrations of circulating IL9 in patients with ulcerative colitis and endoscopic score. Data analyzed using Spearman correlation test.

Figure 5 Comparison of IL9, hsCRP and IL6 as potential markers of mucosal non-healing. Data presented as area under ROC curve (AUC) with 95%CI and P value. For an optimal cut-off value, markers sensitivity (sens.) and specificity (spec.) as well as Youden's J statistic (YI, where J = Sensitivity + Specificity - 1) were calculated.